Insiders who reported open-market trades in the last 12 months at the companies Beth C. Seidenberg files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
James B. Tananbaum - $2.52M in LTGO purchases and sales in the last 12 months
Beth C. Seidenberg is a corporate insider, tracked as Director, 10% Owner of Latigo Biotherapeutics, Inc. (LTGO). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Beth C. Seidenberg submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Beth C. Seidenberg been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($720K) across all tracked filings.
Beth C. Seidenberg is Director, 10% Owner of Latigo Biotherapeutics, Inc. (LTGO). 9 SEC Form 4 filings on record going back to 2024, most recently on 11 August 2026. Most recent open-market trade: sold $10K of VERA on 30 October 2024. Lifetime open-market sales: $720K.
Recent transactions
13
The latest 13 SEC Form 4 transactions reported by Beth C. Seidenberg.
InsiderAlpha's records for Beth C. Seidenberg go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. 2 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
